Skip to main
MDLN

Medline Inc (MDLN) Stock Forecast & Price Target

Medline Inc (MDLN) Analyst Ratings

Based on 23 analyst ratings
Buy
Strong Buy 35%
Buy 52%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Medline Inc demonstrated strong financial performance in F2024, with Supply Chain Solutions generating $13 billion in revenue, reflecting a 12% year-over-year growth, while Medline Brand contributed $12.5 billion, up 7.8% year-over-year. The company's robust growth trajectory is evident in its adjusted EBITDA of $3.4 billion for Medline Brand, resulting in a corporate-wide EBITDA margin of 13.2% and a significant increase in Supply Chain Solutions' EBITDA, which rose by 32% year-over-year. Medline's resilience during economic downturns, as indicated by revenue growth during the 2008-2009 financial crisis and the COVID pandemic, underscores its ability to capitalize on the increasing demand for essential medical supplies driven by demographic trends and rising healthcare needs.

Bears say

The financial outlook for Medline Inc is dimmed by several critical factors impacting the healthcare sector, including low margins, elevated inflation, and staffing shortages, all of which are straining hospital profit and loss statements. Furthermore, the potential decline in insured patients may lead to reduced hospital volumes, prompting CFOs to anticipate tighter budgets, thereby threatening Medline's revenues and earnings potential. Additionally, the company's substantial debt load may restrict opportunities for mergers and acquisitions, limiting growth and leaving Medline vulnerable to competitive pressures in an already consolidated industry.

Medline Inc (MDLN) has been analyzed by 23 analysts, with a consensus rating of Buy. 35% of analysts recommend a Strong Buy, 52% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medline Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medline Inc (MDLN) Forecast

Analysts have given Medline Inc (MDLN) a Buy based on their latest research and market trends.

According to 23 analysts, Medline Inc (MDLN) has a Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.74, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.74, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medline Inc (MDLN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.